Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.

Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, Kreiniz N, Tadmor T, Trestman S, Vitkon R, Rouvio O, Shvetz O, Shaulov A, Ziv-Baran T, Avivi I.

Ann Hematol. 2020 Mar 20. doi: 10.1007/s00277-020-03985-9. [Epub ahead of print]

PMID:
32193630
2.

The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants.

Raz MA, Arnason J, Bairey O, Shvidel L, Aviv A, Ben Baruch S, Perry C, Sarid N, Kirgner I, Dvid V, Herishanu Y, Avivi I.

Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16422. [Epub ahead of print] No abstract available.

PMID:
32150642
3.

Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma.

Luttwak E, Amit O, Avivi I, Trestman S, Eshel R, Cohen YC, Ram R.

Eur J Haematol. 2020 Mar 3. doi: 10.1111/ejh.13404. [Epub ahead of print]

PMID:
32124519
4.

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.

Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Davila Valls J, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Długosz-Danecka M, Grosicki S, Vesole DH.

Am J Hematol. 2020 Feb 18. doi: 10.1002/ajh.25758. [Epub ahead of print]

PMID:
32072687
5.

Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.

Katodritou E, Kastritis E, Gatt M, Cohen YC, Avivi I, Pouli A, Lalayianni C, Lavi N, Delimpasis S, Kyrtsonis MC, Michael M, Suriu C, Miri Z, Tzafarti K, Vadikoliou C, Maltezas D, Zikos P, Ganzel C, Vaxman Y, Aviv A, Christoforidou A, Gavriatopoulou M, Shaulov A, Verrou E, Papanota AM, Fakinos G, Gkioka AI, Palaska V, Triantafyllou T, Konstantinidou P, Anagnostopoulos A, Terpos E, Dimopoulos MA.

Am J Hematol. 2020 Feb 12. doi: 10.1002/ajh.25755. [Epub ahead of print]

PMID:
32048329
6.

Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution.

Mamet N, Amir Y, Lavi E, Bassali L, Harari G, Rusinek I, Skalka N, Debby E, Greenberg M, Zamir A, Paz A, Reiss N, Loewenthal G, Avivi I, Shimoni A, Neev G, Abu-Horowitz A, Bachelet I.

Commun Biol. 2020 Jan 15;3(1):29. doi: 10.1038/s42003-020-0756-0.

7.

Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.

Shimony S, Horowitz N, Ribakovsky E, Rozovski U, Avigdor A, Zloto K, Berger T, Avivi I, Perry C, Abadi U, Raanani P, Gafter-Gvili A, Gurion R.

Hematol Oncol. 2019 Dec;37(5):569-577. doi: 10.1002/hon.2691. Epub 2019 Nov 25.

PMID:
31674027
8.

Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.

Barzilai M, Kirgner I, Steimatzky A, Salzer Gotler D, Belnick Y, Shacham-Abulafia A, Avivi I, Raanani P, Yahalom V, Nakav S, Varon D, Yussim E, Bachar GN, Spectre G.

Acta Haematol. 2019 Oct 14:1-6. doi: 10.1159/000502173. [Epub ahead of print]

PMID:
31610537
9.

Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.

Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, Shmakov RG, Bellido M, Cabrera-Garcia A, Gziri MM, Halaska MJ, Ottevanger PB, Van Calsteren K, O'Laughlin A, Polushkina E, Van Dam L, Avivi I, Vandenberghe P, Woei-A-Jin FJSH, Amant F; International Network on Cancer, Infertility and Pregnancy.

Lancet Haematol. 2019 Nov;6(11):e551-e561. doi: 10.1016/S2352-3026(19)30195-4. Epub 2019 Sep 26. Erratum in: Lancet Haematol. 2020 Apr;7(4):e279.

PMID:
31564649
10.

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.

Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, Timaner M, Avraham S, Hayun M, Lavi N, Bersudsky M, Voronov E, Apte RN, Shaked Y.

Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13.

PMID:
31409628
11.

Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.

Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wiśniewska-Piąty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A.

Am J Hematol. 2019 Oct;94(10):1132-1140. doi: 10.1002/ajh.25579. Epub 2019 Aug 13.

PMID:
31334859
12.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators.

Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.

PMID:
31327689
13.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
14.

Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.

Perry C, Ben Barouch S, Goldschmidt N, Sarid N, Herishanu Y, Shvidel L, Bairey O, Lavi N, Horowitz N, Avigdor A, Lebel E, Sofer O, Ram R, Avivi I.

Am J Hematol. 2019 Sep;94(9):992-1001. doi: 10.1002/ajh.25558. Epub 2019 Jun 18.

PMID:
31211434
15.

Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.

Ram R, Amit O, Zuckerman T, Gurion R, Raanani P, Bar-On Y, Avivi I, Wolach O.

Ann Hematol. 2019 Aug;98(8):1927-1932. doi: 10.1007/s00277-019-03719-6. Epub 2019 Jun 11.

PMID:
31187237
16.

Interim PET-CT-guided therapy in elderly patients with Hodgkin lymphoma-a retrospective national multi-center study.

Bentur OS, Dann EJ, Paran E, Lavie D, Nachmias B, Ron Y, Dally N, Gutwein O, Herishanu Y, Sarid N, Avivi I, Perry C.

Ann Hematol. 2019 Jul;98(7):1665-1674. doi: 10.1007/s00277-019-03686-y. Epub 2019 May 18.

PMID:
31104090
17.

Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in aging.

Avivi I, Zisman-Rozen S, Naor S, Dai I, Benhamou D, Shahaf G, Tabibian-Keissar H, Rosenthal N, Rakovsky A, Hanna A, Shechter A, Peled E, Benyamini N, Dmitrukha E, Barshack I, Mehr R, Melamed D.

Aging Cell. 2019 Aug;18(4):e12959. doi: 10.1111/acel.12959. Epub 2019 May 6.

18.

Current treatment of lymphoma in pregnancy.

Gurevich-Shapiro A, Avivi I.

Expert Rev Hematol. 2019 Jun;12(6):449-459. doi: 10.1080/17474086.2019.1615878. Epub 2019 May 20.

PMID:
31055974
19.

Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms.

Barzilai M, Kirgner I, Avivi I, Ellis M, Dally N, Rozovski U, Lavi N.

Eur J Haematol. 2019 Jun;102(6):504-508. doi: 10.1111/ejh.13232. Epub 2019 Apr 25.

PMID:
30941804
20.

Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.

Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U.

Haematologica. 2019 Sep;104(9):1798-1803. doi: 10.3324/haematol.2018.203869. Epub 2019 Feb 7.

21.

Hematological malignancies during pregnancy.

Barzilai M, Avivi I, Amit O.

Mol Clin Oncol. 2019 Jan;10(1):3-9. doi: 10.3892/mco.2018.1759. Epub 2018 Nov 8. Review.

22.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
23.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I.

Nat Med. 2018 Dec;24(12):1867-1876. doi: 10.1038/s41591-018-0269-2. Epub 2018 Dec 6.

PMID:
30523328
24.

Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.

Zarfati M, Avivi I, Brenner B, Katz T, Aharon A.

Angiogenesis. 2019 Feb;22(1):185-196. doi: 10.1007/s10456-018-9649-y. Epub 2018 Nov 1.

PMID:
30386953
25.

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center.

Sarid N, Zada M, Lev-Ran S, Yashphe E, Givon I, Barzilai M, Perry C, Avivi I, Wolf I.

Acta Haematol. 2018;140(4):194-202. doi: 10.1159/000493567. Epub 2018 Oct 19.

PMID:
30343297
26.

Ten Things to Know About Primary Mediastinal B Cell Lymphoma.

Avivi I.

Biol Blood Marrow Transplant. 2018 Oct;24(10):1959-1960. doi: 10.1016/j.bbmt.2018.09.010. Epub 2018 Sep 19. No abstract available.

27.

Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study.

Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA.

Am J Hematol. 2018 Sep;93(9):E238-E241. doi: 10.1002/ajh.25209. Epub 2018 Aug 6. No abstract available.

28.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Sep;182(6):807-815. doi: 10.1111/bjh.15454. Epub 2018 Jul 9.

PMID:
29984825
29.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
30.

Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?

Greenbaum U, Joffe E, Filanovsky K, Oster HS, Kirgner I, Levi I, Raanani P, Avivi I, Manor E, Man-El G, Mittelman M.

Eur J Haematol. 2018 Oct;101(4):502-507. doi: 10.1111/ejh.13134. Epub 2018 Aug 31.

PMID:
29956845
31.

Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity.

Barzilai M, Polliack A, Avivi I, Herishanu Y, Ram R, Tang C, Perry C, Sarid N.

Leuk Res. 2018 Aug;71:1-5. doi: 10.1016/j.leukres.2018.06.008. Epub 2018 Jun 17. Review.

PMID:
29920411
32.

Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.

Ram R, Halavy Y, Amit O, Paran Y, Katchman E, Yachini B, Kor S, Avivi I, Ben-Ami R.

Clin Infect Dis. 2018 Sep 28;67(8):1153-1160. doi: 10.1093/cid/ciy258. Erratum in: Clin Infect Dis. 2018 Sep 14;67(7):1151.

PMID:
29608680
33.

Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.

Cohen YC, Saranga A, Gatt ME, Lavi N, Ganzel C, Magen H, Avivi I, Tadmor T, Suriu C, Jarchowsky Dolberg O, Papushado A, Trestman S, Ram R.

Am J Hematol. 2018 Jun;93(6):810-815. doi: 10.1002/ajh.25098. Epub 2018 Apr 28.

34.

Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.

Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group.

Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2.

PMID:
29501828
35.

Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.

Avivi I, Boumendil A, Finel H, Nagler A, de Sousa AB, Santasusana JMR, Vandenberghe E, Afanasyev B, Bordessoule D, Moraleda JM, Garcia EC, Pohlreich D, Garcia GG, Thomson K, Or R, Beelen D, Zuffa E, Giebel S, Berthou C, Salles G, Melpignano A, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 Aug;53(8):1001-1009. doi: 10.1038/s41409-017-0063-7. Epub 2018 Feb 20.

PMID:
29463854
36.

Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.

Ringelstein-Harlev S, Avivi I, Fanadka M, Horowitz NA, Katz T.

Cancer Immunol Immunother. 2018 May;67(5):739-748. doi: 10.1007/s00262-018-2128-x. Epub 2018 Feb 15.

PMID:
29450641
37.

Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma.

Lavi N, Avivi I, Kra-Oz Z, Oren I, Hardak E.

Support Care Cancer. 2018 Jul;26(7):2425-2431. doi: 10.1007/s00520-018-4079-3. Epub 2018 Feb 9.

PMID:
29427192
38.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ.

Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7.

PMID:
29315478
39.

Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.

Shaulov A, Avivi I, Cohen Y, Duek A, Leiba M, Gatt ME.

Amyloid. 2018 Mar;25(1):11-17. doi: 10.1080/13506129.2017.1416350. Epub 2017 Dec 14. Review.

PMID:
29241368
40.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY.

N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

41.

Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study.

Davidov M, Perry C, Herishanu Y, Sarid N, Rom E, Amit O, Eshel R, Naparstek E, Avivi I, Ram R.

Ann Hematol. 2018 Mar;97(3):459-466. doi: 10.1007/s00277-017-3192-6. Epub 2017 Nov 25.

PMID:
29177562
42.

CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines.

Sarid N, Sherban A, Bendet A, Adam S, Herishanu Y, Perry C, Avivi I.

Leuk Lymphoma. 2018 Aug;59(8):1878-1883. doi: 10.1080/10428194.2017.1403023. Epub 2017 Nov 27.

PMID:
29172816
43.

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.

Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M.

Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21.

44.

Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?

Bentur OS, Gurion R, Gafter-Gvili A, Gatt M, Shvidel L, Horowitz NA, Ram R, Herishanu Y, Sarid N, Paltiel O, Ganzel C, Kreiniz N, Dally N, Gutwein O, Raanani P, Avivi I, Perry C.

Leuk Lymphoma. 2018 May;59(5):1163-1171. doi: 10.1080/10428194.2017.1375102. Epub 2017 Sep 13.

PMID:
28901817
45.

The management of hodgkin lymphomas in pregnancies.

Moshe Y, Bentur OS, Lishner M, Avivi I.

Eur J Haematol. 2017 Nov;99(5):385-391. doi: 10.1111/ejh.12956. Epub 2017 Oct 5. Review.

PMID:
28850718
46.

Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.

Horowitz NA, Henig I, Henig O, Benyamini N, Vidal L, Avivi I.

Leuk Lymphoma. 2018 Mar;59(3):610-616. doi: 10.1080/10428194.2017.1347651. Epub 2017 Jul 13.

PMID:
28703077
47.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG.

Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.

48.

Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.

Lavi N, Shapira G, Zilberlicht A, Benyamini N, Farbstein D, Dann EJ, Bar-Shalom R, Avivi I.

Isr Med Assoc J. 2016 Jul;18(7):411-417.

49.

Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews.

Zada M, Lerner D, Piltz Y, Perry C, Avivi I, Herishanu Y.

Eur J Haematol. 2017 Jul;99(1):51-55. doi: 10.1111/ejh.12889. Epub 2017 May 3.

PMID:
28370385
50.

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.

Shapiro M, Herishanu Y, Katz BZ, Dezorella N, Sun C, Kay S, Polliack A, Avivi I, Wiestner A, Perry C.

Haematologica. 2017 May;102(5):874-882. doi: 10.3324/haematol.2016.148965. Epub 2017 Feb 2.

Supplemental Content

Support Center